Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
β-catenin fragment 529-581 mRNA-LNP
- Development stage
- Preclinical
- Lead developer
- Stowers Institute for Medical Research
- Modality
- Peptides, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
β-catenin fragment 529-581 mRNA-LNP is an experimental mRNA-based therapeutic designed to target leukemia stem cells (LSCs) by disrupting the AKT-Wnt/β-catenin signaling pathway. Developed by researchers at the Stowers Institute for Medical Research, this drug utilizes lipid nanoparticle (LNP) technology to deliver mRNA encoding a specific 53-amino acid fragment (residues 529-581) of the β-catenin protein. This fragment acts as a peptide inhibitor that interferes with the interaction between AKT and β-catenin, specifically targeting the AKT phosphorylation site at Ser552. By inhibiting this pathway, the treatment aims to reduce LSC self-renewal, overcome chemoradiotherapy resistance, and reprogram anti-tumor immunity in conditions such as acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL).
- Other names
- β-catenin 529-581 mRNA-LNPbeta-catenin fragment 529-581 mRNA-LNP
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)BCL9/BCL9L (B-cell CLL/lymphoma 9 and B-cell CLL/lymphoma 9-like protein)TCF/LEF (T-cell factor/lymphoid enhancer-binding factor transcription factors)
Beyond the preview
Go deeper on β-catenin fragment 529-581 mRNA-LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on β-catenin fragment 529-581 mRNA-LNP.